Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis

References

• Towler HMA, Whiting PH, Forrester JV. Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation. Eye 1990;4:514–520.
   Google Scholar
• Whitcup SM, Salvo EC, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçee s disease. Am J Ophthalmol 1994;118:39–45.
   Google Scholar
• Dick AD, Azim MA, Forrester JV. Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol 1997;81:1107–1112.
   Google Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory noninfectious childhood uveitis. Br J Ophthalmol 1998; in press.
   Google Scholar
• Dick AD. Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis? Br J Ophthalmol 1995;79:81–88.
   PubMed Web of Science ®Google Scholar
• Isaacs I, Dick AD. Short term immunosuppressive therapy and long term immunoregulation: promises and problems. Br J Ophthalmol 1996;80:1035–1037.
   PubMed Web of Science ®Google Scholar
• Tamesis RR, Rodriguez A, Christen WG, Akova YA, Messmer E, Foster CS. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology 1996;103:768–775.
   PubMed Web of Science ®Google Scholar
• Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic noninfectious uveitis. Ophthalmology 1996;103:365–374.
   Google Scholar
• Nussenblatt RB, Whitcup SM, Palestine AG. Philosophy, goals, and approaches to medical therapy. In: Nussenblatt RB, Whitcup SM, Palestine AG, editors. Uveitis: Fundamentals and Clinical Practice, 2nd ed. St. Louis: Mosby, 1996; 97–134.
   Google Scholar
• Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991;35:369–385.
   Google Scholar
• Lane L, Tamesis R, Rodriguez A, et al. Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Ophthalmology 1995;102:1530–1535.
   PubMed Web of Science ®Google Scholar
• Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK506, a novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics. J Antibiot 1987;40:1249–1255.
   Google Scholar
• Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK506 in vitro. J Antibiot 1987;40: 1256–1265.
   Google Scholar
• Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506: in vitro effects on the cloned T cell activation. J Immunol 1987139:1797-1803.
   PubMed Web of Science ®Google Scholar
• Tocci M, Matkovitch DA, Colier KA, Kwok P, Dumont F, Lin S, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989;143:718–726.
   PubMed Web of Science ®Google Scholar
• Sanchez ER, Ning YM. Immunophilins, heat shock proteins, and glucocorticoid receptor actions in vivo. Methods 1996;9(2):188–200.
   PubMedGoogle Scholar
• Ning YM, Sanchez ER. Stabilization in vitro of the untransformed glucocorticoid receptor complex of S49 lynphocytes by the immunophilin ligand FK506. J Steroid Biochem Mol Biol 1995;52(2):187–194.
   PubMed Web of Science ®Google Scholar
• European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423–428.
   Google Scholar
• The US Multicentre FK506 Liver Study Group. A comparison of tacrolimus and cyclosporin for immunosuppression in liver transplantation. New Engl J Med 1994;331:1110–1115.
   Google Scholar
• Kawashima H, Fujino Y, Mochizuki M. Effects of a new immunosuppres-sive agent, FK506, on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 1988;29: 1265–1271.
   Google Scholar
• Kawashima H, Fujino Y, Mochizuki M. Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. Invest Ophthalmol Vis Sci 1990;31: 2500–2507.
   Google Scholar
• Kawashima H, Mochizuki M. Effects of a new immunosuppressive agent, FK506, on the efferent limb of the immune responses. Exp Eye Res 1990;51:565–572.
   PubMed Web of Science ®Google Scholar
• Fujino Y, Mochizuki M, Chan CC, Raber J, Kotake S, Gery I, et al. FK506 treatment of S-antigen induced uveitis in primates. Curr Eye Res 1991;1o:679-69o.
   Google Scholar
• Mochizuki M, Ikeda E, Shirao M, Fujito S, Yoshimura K, Shimada N. Preclinical and clinical study of FK506 in uveitis. Curr Eye Res 1992;11:S87–95.
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Masuda K, Sakane T, Ito K, Kogure M, Sugino N, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993;115:763–769.
   PubMed Web of Science ®Google Scholar
• Ishioka M, Ohno S, Nakamura S, Isobe K, Watanabe N, Ishigatsubo Y, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994;118:723–729.
   PubMed Web of Science ®Google Scholar
• Sakane T, Mochizuki M, Inaba G, Masuda K. A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions. Ryumachi 1995;35(5):802–813.
   PubMedGoogle Scholar
• Mishima S, Masuda K, Izawa Y, et al. Behçet's disease in Japan: ophthalmological aspects. Trans Am Ophthalmol Soc 1979;76:225–279.
   Google Scholar
• Dinning WJ. Behçet's syndrome. In: Gold DH, Weingeist TA, editors. The Eye in Systemic Disease. Philadelphia: JB Lippincott, 1990; 279–281.
   Google Scholar
• O'Duffy JD. Behçet's syndrome. New Engl J Med 1990;322:326–328.
   PubMedGoogle Scholar
• Wechsler B, Piette JC. Behçet's disease. Br Med J 1992;304;1199–1200.
   PubMedGoogle Scholar
• Nussenblatt RB. Behçet's disease. In: Nussenblatt RB, Whitcup SM, Palestine AG, editors. Uveitis: Fundamentals and Clinical Practice, 2nd ed. St. Louis: Mosby, 1996; 334–353.
   Google Scholar
• Nussenblatt RB. Vogt-Koyanagi-Harada syndrome. In: Nussenblatt RB, Whitcup SM, Palestine AG, editors. Uveitis: Fundamentals and Clinical Practice, 2nd ed. St. Louis: Mosby, 1996; 312–324.
   Google Scholar
• Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987;103:234-235. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Am J Ophthalmol 1985;92: 467–471.
   Google Scholar
• BenEzra D, Forrester JV, Nussenblatt RB, Tabbara K, Timonen P. Uveitis Scoring System. Berlin: Springer-Verlag, 1992; 1–13.
   Google Scholar
• Feutren G, Mihatsch M. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992;326:1654–1660.
   PubMed Web of Science ®Google Scholar
• Tugwell P. International consensus recommendations on cyclosporin use in rheumatoid arthritis. Drugs 1995;50:48–56.
   PubMed Web of Science ®Google Scholar
• Schwartz GJ, Haycock GB, Spitzer A. Plasma creatinine and urea concentration in children. Normal values for age and sex. J Pediatr 1976;88:828–830.
   Google Scholar
• International Study Group for Behçee s Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078–1080.
   PubMed Web of Science ®Google Scholar
• Shapiro R, Fung JJ, Jain AB, Parks P, Todo S, Starzl TE. The side effects of FK506 in humans. Transplant Proc 1990;22:35–36.
   PubMed Web of Science ®Google Scholar
• The US Multicentre FK506 Liver Study Group. Tacrolimus compared with cyclosporin for primary immunosuppression after paediatric liver transplantation. Transplantation 1995;59(4):530–536.
   Google Scholar
• Bishop DK, Li W. Cyclosporin and FK506 mediate differential effects on T cell activation in vivo. J Immunol 1989;148(4):1049–1054
   Google Scholar